The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

(2014) Stephen M.F. Jamieson et al.   BIOCHEMICAL PHARMACOLOGY

High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

(2013) D. Lin et al.   CANCER RESEARCH

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

(2013) M. Yepuru et al.   CLINICAL CANCER RESEARCH

Deeper Insight into the Reducing Biotransformation of Bupropion in the Human Liver

(2013) Lucie Skarydova et al.   Drug Metabolism and Pharmacokinetics

Synthesis and structure–activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3

(2013) Daniel M. Heinrich et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

AKR1C3 as a target in castrate resistant prostate cancer

(2013) Adegoke O. Adeniji et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Unknown

(2013) Agus Hamid et al.   MOLECULAR MEDICINE

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors

(2012) N. Mitsiades et al.   CANCER RESEARCH

Activin A StimulatesAKR1C3Expression and Growth in Human Prostate Cancer

(2012) Johannes Hofland et al.   ENDOCRINOLOGY

3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-β-Hydroxysteroid Dehydrogenase AKR1C3

(2012) Stephen M. F. Jamieson et al.   JOURNAL OF MEDICINAL CHEMISTRY

A New Nonestrogenic Steroidal Inhibitor of 17 -Hydroxysteroid Dehydrogenase Type I Blocks the Estrogen-Dependent Breast Cancer Tumor Growth Induced by Estrone

(2012) D. Ayan et al.   MOLECULAR CANCER THERAPEUTICS

Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors

(2011) C. Cai et al.   CANCER RESEARCH

Unknown

(2011) Minja Pfeiffer et al.   MOLECULAR MEDICINE

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

(2011) K.-H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan

(2010) Mikhail G Dozmorov et al.   BMC CANCER

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

(2010) C. P. Guise et al.   CANCER RESEARCH

Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer

(2010) J. Hofland et al.   CANCER RESEARCH

Steroid Hormone Transforming Aldo-Keto Reductases and Cancer

(2009) Trevor M. Penning et al.   Annals of the New York Academy of Sciences

Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds

(2009) A.Kenneth MacLeod et al.   CARCINOGENESIS

Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer

(2009) Michael C. Byrns et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers

(2009) Pedro Veliça et al.   Molecular Cancer

The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis

(2009) Jane Birtwistle et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

In situestrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology

(2009) Hironobu Sasano et al.   PATHOLOGY INTERNATIONAL

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes

(2008) Jonine D. Figueroa et al.   CARCINOGENESIS

Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast

(2008) R. Shibuya et al.   ENDOCRINE-RELATED CANCER

17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer

(2008) Joanna M. Day et al.   INTERNATIONAL JOURNAL OF CANCER

Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors

(2008) Yannick Laplante et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Inactivation of the anticancer drugs doxorubicin and oracin by aldo–keto reductase (AKR) 1C3

(2008) Romana Novotna et al.   TOXICOLOGY LETTERS

Mechanisms mediating androgen receptor reactivation after castration

(2008) Xin Yuan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS